Announcements Trials
Browse Landscape

Phase

Phase 2 24Phase 1 14Phase 1/2 11Phase 3 3Phase EARLY_PHASE1 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 19Carcinoma 4NSCLC 3Lung Neoplasms 3Neoplasm Metastasis 2Stage IB-IIIA Non-small Cell Lung Carcinoma 1Non-small Cell Carcinoma 1Neoplasms 1Neoplasm, Residual 1NSCLC Patients With Brain Metastasis 1Locally Advanced or Metastatic Non-squamous NSCLC 1Locally Advanced or Metastatic EGFR T790M+ NSCLC 1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer 1Bronchial Neoplasms 1Brain Neoplasms 1Anticancer Treatment 1

Interventions

Carboplatin 66Cisplatin 57Paclitaxel 42Radiotherapy 35Pemetrexed 34Gemcitabine 31Docetaxel 31Etoposide 24pembrolizumab 21Vinorelbine 20Erlotinib Hydrochloride 13Magnetic Resonance Spectroscopy 12Gefitinib 11Specimen Handling 10Radiosurgery 10Drug Therapy 10Bevacizumab 10durvalumab 9Nivolumab 9Vinblastine 6Topotecan 6Surgical Procedures, Operative 6Cyclophosphamide 6Standard of Care 5Platinum 5Immunoglobulin G 5Ifosfamide 5Disulfides 5Dexamethasone 5paclitaxel poliglumex 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Lung Neoplasms × osimertinib × Clear all
NCT04181060 2026-05-18

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

National Cancer Institute (NCI)

Phase 3 Recruiting
300 enrolled
Thoracic

Lung Neoplasms

NCT05624996 2026-05-04

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

NRG Oncology

Phase 3 Recruiting
474 enrolled
Thoracic

Lung Neoplasms

NCT06323148 2024-03-21

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Fudan University

Phase 3 Not yet recruiting
226 enrolled
Thoracic

Lung Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡